New-onset atrial fibrillation at the IMT (Internal Medicine Training) clinical station is answered in three moves: decide whether the patient is haemodynamically stable, place the onset either side of 48 hours, and score the stroke risk. NICE NG196 recommends emergency electrical cardioversion, without delaying to achieve anticoagulation, in life-threatening haemodynamic instability caused by new-onset atrial fibrillation.

Key takeaways

  • NICE NG196 recommends a 12-lead ECG to make the diagnosis of atrial fibrillation when an irregular pulse is found, with or without symptoms.
  • Life-threatening haemodynamic instability caused by new-onset atrial fibrillation means emergency electrical cardioversion, without delaying to achieve anticoagulation.
  • Without life-threatening instability, NICE NG196 offers either rate or rhythm control if onset was less than 48 hours ago, and rate control if onset was more than 48 hours ago or is uncertain.
  • If the arrhythmia has lasted more than 48 hours or the duration is uncertain and rhythm control is planned, cardioversion is delayed until the patient has had therapeutic anticoagulation for a minimum of three weeks.
  • Stroke risk uses CHA2DS2-VASc: NICE NG196 offers a direct-acting oral anticoagulant at a score of 2 or above, and says to consider one for men with a score of 1.
  • Bleeding risk uses ORBIT in atrial fibrillation, and NICE NG196 says not to withhold anticoagulation solely because of age or a risk of falls.

How do you recognise new-onset atrial fibrillation in the scenario?

New-onset atrial fibrillation presents as palpitations, breathlessness, chest discomfort, syncope or dizziness, or as a stroke or transient ischaemic attack, and NICE NG196 lists exactly those as prompts for pulse palpation.

The station usually hands you an irregularly irregular pulse in a patient who is unwell for another reason. Say that atrial fibrillation is often the symptom, not the disease.

NICE NG196 recommends a 12-lead ECG to confirm the diagnosis, and specifically to avoid relying on less accurate single-lead devices. Say 12-lead rather than just ECG.

What does the A to E assessment and the first hour look like?

The first hour of new-onset atrial fibrillation is an A to E assessment whose purpose is a single question: is this patient haemodynamically unstable? The answer changes everything that follows.

  • Airway and breathing: saturations and respiratory rate, looking for pulmonary oedema, which suggests the atrial fibrillation is decompensating a failing heart
  • Circulation: blood pressure, perfusion, conscious level and a 12-lead ECG; shock, syncope, myocardial ischaemia or heart failure define life-threatening instability
  • Disability: conscious level, and a focused neurological examination because the presentation may be a stroke
  • Exposure: temperature and a search for the precipitant, since sepsis, alcohol, thyrotoxicosis, pulmonary embolism and electrolyte disturbance all trigger atrial fibrillation
  • Anticoagulation: NICE NG196 says to offer heparin at initial presentation, in the absence of contraindications, to people with new-onset atrial fibrillation who are on no or subtherapeutic anticoagulation

However, the phrase that earns the mark is precise. NICE NG196 reserves emergency electrical cardioversion for life-threatening haemodynamic instability, and says it is done without delaying to achieve anticoagulation.

Which investigations does new-onset atrial fibrillation need?

The investigations in new-onset atrial fibrillation are the 12-lead ECG that makes the diagnosis, plus the tests that find the precipitant and the tests that make anticoagulation safe.

  • Full blood count, urea and electrolytes including magnesium and calcium, and liver function, because renal and hepatic function decide anticoagulant choice and dose
  • Thyroid function tests, since thyrotoxicosis is the treatable cause candidates forget
  • Chest X-ray for infection, heart failure and other precipitants, and a troponin only if there is clinical suspicion of an acute coronary syndrome
  • Transthoracic echocardiography to assess structure and function, which also decides whether flecainide can be used for pharmacological cardioversion
  • For suspected paroxysmal atrial fibrillation undetected on a 12-lead ECG, NICE NG196 recommends a 24-hour ambulatory monitor if episodes are less than 24 hours apart, and a longer-duration device if they are further apart

What is the 48-hour rule, and what does it change?

The threshold that decides management in new-onset atrial fibrillation is 48 hours from the onset of the arrhythmia. NICE NG196 offers either rate or rhythm control if onset is less than 48 hours ago, and rate control if onset is more than 48 hours ago or uncertain.

That rule exists because atrial thrombus forms with time, so cardioverting a patient whose atrial fibrillation is older than 48 hours risks embolising a clot you cannot see.

  • If duration is over 48 hours or uncertain and long-term rhythm control is being considered, NICE NG196 says to delay cardioversion until the patient has been on therapeutic anticoagulation for a minimum of three weeks, offering rate control meanwhile
  • If the precise time of onset is uncertain in new-onset atrial fibrillation, offer oral anticoagulation as you would for persistent atrial fibrillation
  • For confirmed atrial fibrillation of less than 48 hours, offer oral anticoagulation if sinus rhythm is not restored within that 48-hour period, or if there are factors indicating a high risk of recurrence such as failed cardioversion, structural heart disease or atrial fibrillation lasting more than 12 months

Give the number, not the adjective. A candidate who says 'recent onset' has not shown the panel where the cardioversion decision actually turns.

What is the definitive management of new-onset atrial fibrillation?

Definitive management of new-onset atrial fibrillation is rate control for most patients, rhythm control for selected ones, and anticoagulation decided separately on stroke risk rather than on rhythm.

  • Rate control first line, except where NICE NG196 lists exceptions: a reversible cause, heart failure thought to be primarily caused by the atrial fibrillation, new-onset atrial fibrillation, atrial flutter suitable for ablation, or clinical judgement favouring rhythm control
  • Initial rate-control monotherapy is a standard beta-blocker, meaning any beta-blocker other than sotalol, or a rate-limiting calcium-channel blocker, diltiazem or verapamil
  • Digoxin monotherapy is considered for non-paroxysmal atrial fibrillation if the person does no or very little physical exercise, or if other rate-limiting drugs are ruled out
  • If monotherapy fails, consider any two of a beta-blocker, diltiazem and digoxin; NICE NG196 says not to offer amiodarone for long-term rate control
  • For pharmacological cardioversion of new-onset atrial fibrillation, offer a choice of flecainide or amiodarone with no structural or ischaemic heart disease, and amiodarone if there is structural heart disease
  • NICE NG196 says not to offer magnesium or a calcium-channel blocker for pharmacological cardioversion

In practice the trap is concomitant heart failure. NICE NG196 says to seek senior specialist input on beta-blockers in suspected acute decompensated heart failure, and not to use calcium-channel blockers at all.

Anticoagulation in new-onset atrial fibrillation uses CHA2DS2-VASc. NICE NG196 offers a direct-acting oral anticoagulant at a score of 2 or above, considers one for men scoring 1, and says not to offer stroke prevention to people under 65 with no risk factors other than their sex.

When and to whom do you escalate new-onset atrial fibrillation?

Escalate new-onset atrial fibrillation immediately when there is life-threatening haemodynamic instability, because that patient needs emergency electrical cardioversion and therefore needs a senior, an anaesthetist and a resuscitation area.

Call cardiology for suspected acute decompensated heart failure, for a pre-excited rhythm, and whenever rhythm control is being considered outside the 48-hour window.

For follow-up, NICE NG196 says to refer promptly at any stage if treatment fails to control symptoms, within four weeks of the failed treatment or of recurrence after cardioversion.

How do you hand over new-onset atrial fibrillation in one minute?

The new-onset atrial fibrillation handover uses SBAR and puts the onset time and the blood pressure in the first sentence, because those two facts decide what the receiving team does.

Situation: a 74 year old with atrial fibrillation at 140 beats per minute, onset about six hours ago, blood pressure 128 over 74. Background: hypertension and type 2 diabetes, on no anticoagulant.

Assessment: new-onset atrial fibrillation under 48 hours, haemodynamically stable, no heart failure, likely precipitant is a urinary tract infection. Recommendation: heparin started, rate control with a beta-blocker, CHA2DS2-VASc is 4 so please review for a direct-acting oral anticoagulant today.

What does the panel listen for in a new atrial fibrillation answer?

The panel listens for the stability question asked first, the 48-hour rule said as a number, the three-week anticoagulation delay before cardioversion, and CHA2DS2-VASc with ORBIT rather than a vague mention of bleeding risk.

In practice they also mark whether you hunt the precipitant, because the scenario is usually written so that treating the sepsis or the thyrotoxicosis is what fixes the rhythm. The internalmedicineinterview bank, 361 questions across 56 scenarios with AI-marked spoken practice, drills those numbers against the clock.

What are the common mistakes in a new atrial fibrillation station?

  • Cardioverting an unstable patient only after arranging anticoagulation, when the guideline says not to delay
  • Offering rhythm control when the onset is uncertain or older than 48 hours
  • Reaching for HAS-BLED in atrial fibrillation; NICE NG196 recommends ORBIT, and HAS-BLED belongs to long-term venous thromboembolism decisions in NICE NG158
  • Using a bleeding score as a reason to withhold anticoagulation, or withholding it because the patient is old or falls
  • Giving a calcium-channel blocker to a patient with suspected acute decompensated heart failure
  • Treating the rhythm and never looking for sepsis, alcohol, thyrotoxicosis or pulmonary embolism

How this comes up at the IMT interview

New-onset atrial fibrillation maps onto all three parts of the IMT clinical station. Investigations and diagnosis is the 12-lead ECG, the thyroid function and the search for a precipitant; management is the stability question, then the 48-hour rule, then anticoagulation; and communication is explaining to a patient who feels well why they now need a lifelong anticoagulant.

The handover minute is where the onset time, the blood pressure and the CHA2DS2-VASc score have to be said in order, with a clear ask and a time for review.